메뉴 건너뛰기




Volumn 18, Issue 1, 2013, Pages 97-107

Emerging mitotic inhibitors for non-small cell carcinoma

Author keywords

Anti microtubule agents; Aurora kinases; Epothilones; Eribulin; KEP; Mitosis; Nab paclitaxel; Polo like kinase

Indexed keywords

1 CYCLOPROPYL 3 [3 (5 MORPHOLINOMETHYL 1H BENZIMIDAZOL 2 YL) 1H PYRAZOL 4 YL]UREA; 4 (8 CYCLOPENTYL 7 ETHYL 5,6,7,8 TETRAHYDRO 5 METHYL 6 OXO 2 PTERIDINYLAMINO) 3 METHOXY N (1 METHYL 4 PIPERIDINYL)BENZAMIDE; 4 [[9 CHLORO 7 (2,6 DIFLUOROPHENYL) 5H PYRIMIDO[5,4 D][2]BENZAZEPIN 2 YL]AMINO]BENZOIC ACID; 9,10 DIDEHYDROEPOTHILONE D; AURORA A KINASE; BEVACIZUMAB; CARBOPLATIN; CISPLATIN; CRIZOTINIB; DOCETAXEL; EPOTHILONE A; EPOTHILONE B; EPOTHILONE D; ERIBULIN; ERLOTINIB; GEMCITABINE; HESPERIDIN; ISPINESIB; IXABEPILONE; KINESIN; MNL 8054; MNL 8237; NANOPARTICLE; NAVELBINE; PACLITAXEL; POLO LIKE KINASE 1; SAGOPILONE; TOZASERTIB; UNCLASSIFIED DRUG; UNINDEXED DRUG; VOLASERTIB;

EID: 84874632972     PISSN: 14728214     EISSN: None     Source Type: Journal    
DOI: 10.1517/14728214.2013.777426     Document Type: Review
Times cited : (12)

References (62)
  • 1
    • 78049485263 scopus 로고    scopus 로고
    • Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008
    • Ferlay J, Shin HR, Bray F, et al. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer 2010;127:2893-917
    • (2010) Int J Cancer , vol.127 , pp. 2893-2917
    • Ferlay, J.1    Shin, H.R.2    Bray, F.3
  • 3
    • 77952583078 scopus 로고    scopus 로고
    • Recent issues in first-line treatment of advanced non-small-cell lung cancer: Results of an International Expert Panel Meeting of the Italian Association of Thoracic Oncology
    • Gridelli C, Ardizzoni A, Douillard J-Y, et al. Recent issues in first-line treatment of advanced non-small-cell lung cancer: results of an International Expert Panel Meeting of the Italian Association of Thoracic Oncology. Lung Cancer 2010;68:319-31
    • (2010) Lung Cancer , vol.68 , pp. 319-331
    • Gridelli, C.1    Ardizzoni, A.2    Douillard, J.-Y.3
  • 4
    • 33846523617 scopus 로고    scopus 로고
    • Targeted anti-mitotic therapies: Can we improve on tubulin agents?
    • DOI 10.1038/nrc2049, PII NRC2049
    • Jackson JR, Patrick DR, Dar MM, Huang PS. Targeted anti-mitotic therapies: can we improve on tubulin agents? Nat Rev Cancer 2007;7:107-17 (Pubitemid 46160987)
    • (2007) Nature Reviews Cancer , vol.7 , Issue.2 , pp. 107-117
    • Jackson, J.R.1    Patrick, D.R.2    Dar, M.M.3    Huang, P.S.4
  • 5
    • 63449117144 scopus 로고    scopus 로고
    • Beyond taxanes: A review of novel agents that target mitotic tubulin and microtubules, kinases, and kinesins
    • Harrison MR, Holen KD, Liu G. Beyond taxanes: a review of novel agents that target mitotic tubulin and microtubules, kinases, and kinesins. Clin Adv Hematol Oncol 2009;7(1):54-64
    • (2009) Clin Adv Hematol Oncol , vol.7 , Issue.1 , pp. 54-64
    • Harrison, M.R.1    Holen, K.D.2    Liu, G.3
  • 7
    • 33747887418 scopus 로고    scopus 로고
    • Nab-paclitaxel-, a novel, Cremophor- EL-free albumin-bound particle form of paclitaxel for the treatment of advanced non-small cell lung cancer
    • Green MR, Manikhas GM, Orlov S, et al. Nab-paclitaxel-, a novel, Cremophor- EL-free albumin-bound particle form of paclitaxel for the treatment of advanced non-small cell lung cancer. Ann Oncol 2006;17(8):1263-8
    • (2006) Ann Oncol , vol.17 , Issue.8 , pp. 1263-1268
    • Green, M.R.1    Manikhas, G.M.2    Orlov, S.3
  • 9
    • 77953150067 scopus 로고    scopus 로고
    • A dose finding study of weekly and every-3-week nab-paclitaxel followed by carboplatin as first-line therapy in patients with advanced non-small cell lung cancer
    • Socinski MA, Manikhas GM, Stroyakovsky DL, et al. A dose finding study of weekly and every-3-week nab-paclitaxel followed by carboplatin as first-line therapy in patients with advanced non-small cell lung cancer. J Thorac Oncol 2010;5:852-61
    • (2010) J Thorac Oncol , vol.5 , pp. 852-861
    • Socinski, M.A.1    Manikhas, G.M.2    Stroyakovsky, D.L.3
  • 10
    • 84863957748 scopus 로고    scopus 로고
    • Weekly nab-paclitaxel in combination with carboplatin versus solvent-based paclitaxel and carboplatin as first-line therapy in patients with advanced non-small-cell lung cancer: Final results of a phase III trial
    • Socinski MA, Bondarenko I, Karaseva N, et al. Weekly nab-paclitaxel in combination with carboplatin versus solvent-based paclitaxel and carboplatin as first-line therapy in patients with advanced non-small-cell lung cancer: final results of a phase III trial. J Clin Oncol 2012;30:2055-62
    • (2012) J Clin Oncol , vol.30 , pp. 2055-2062
    • Socinski, M.A.1    Bondarenko, I.2    Karaseva, N.3
  • 11
    • 84873866422 scopus 로고    scopus 로고
    • Safety and efficacy of weekly nab- paclitaxel in combination with carboplatin as first-line therapy in elderly patients with advanced non-small-cell lung cancer
    • Socinski MA, Langer CJ, Okamoto I, et al. Safety and efficacy of weekly nab- paclitaxel in combination with carboplatin as first-line therapy in elderly patients with advanced non-small-cell lung cancer. Ann Oncol 2013;24(2):314-21
    • (2013) Ann Oncol , vol.24 , Issue.2 , pp. 314-321
    • Socinski, M.A.1    Langer, C.J.2    Okamoto, I.3
  • 12
    • 74249105385 scopus 로고    scopus 로고
    • Phase II trial of albumin-bound paclitaxel + carboplatin + bevacizumab in first-line patients with advanced nonsquamous non-small cell lung cancer
    • Reynolds C, Barrera D, Jotte R, et al. Phase II trial of albumin-bound paclitaxel + carboplatin + bevacizumab in first-line patients with advanced nonsquamous non-small cell lung cancer. J Thorac Oncol 2009;4(12):1-7
    • (2009) J Thorac Oncol , vol.4 , Issue.12 , pp. 1-7
    • Reynolds, C.1    Barrera, D.2    Jotte, R.3
  • 13
    • 84874602796 scopus 로고    scopus 로고
    • In vivo assessment of the effects of bevacizumab in advanced non-small cell lung cancer (NSCLC)
    • Heist RS, Duda GD, Sahani D, et al. In vivo assessment of the effects of bevacizumab in advanced non-small cell lung cancer (NSCLC). J Clin Oncol 2010;28(15s Suppl):abstract 7612
    • (2010) J Clin Oncol , vol.28 , Issue.15 SUPPL.
    • Heist, R.S.1    Duda, G.D.2    Sahani, D.3
  • 14
    • 3042701597 scopus 로고    scopus 로고
    • Epothilones: Mechanism of action and biologic activity
    • DOI 10.1200/JCO.2004.12.001
    • Goodin S, Kane MP, Rubin EH. Epothilones: mechanism of action and biologic activity. J Clin Oncol 2004;22(10):2015-25 (Pubitemid 41095195)
    • (2004) Journal of Clinical Oncology , vol.22 , Issue.10 , pp. 2015-2025
    • Goodin, S.1    Kane, M.P.2    Rubin, E.H.3
  • 15
    • 78650236850 scopus 로고    scopus 로고
    • Chemotherapy, chemoresistance and the changing treatment landscape for NSCLC
    • Chang A. Chemotherapy, chemoresistance and the changing treatment landscape for NSCLC. Lung Cancer 2011;71:3-10
    • (2011) Lung Cancer , vol.71 , pp. 3-10
    • Chang, A.1
  • 16
    • 38449091336 scopus 로고    scopus 로고
    • Potential clinical applications of epothilones: A review of phase II studies
    • Larkin JM, Kaye SB. Potential clinical applications of epothilones: a review of phase II studies. Ann Oncol 2007;18(Suppl 5):v28-34
    • (2007) Ann Oncol , vol.18 , Issue.SUPPL. 5
    • Larkin, J.M.1    Kaye, S.B.2
  • 19
    • 20244376916 scopus 로고    scopus 로고
    • A phase I clinical trial of ixabepilone (BMS-247550), an epothilone B analog, administered intravenously on a daily schedule for 3 days
    • DOI 10.1002/cncr.20977
    • Zhuang S, Agrawal M, Edgerly M, et al. A phase I clinical trial of ixabepilone (BMS-247550), an epothilone B analog, administered intravenously on a daily schedule for 3 days. Cancer 2005;103:1932-8 (Pubitemid 40563267)
    • (2005) Cancer , vol.103 , Issue.9 , pp. 1932-1938
    • Zhuang, S.H.1    Agrawal, M.2    Edgerly, M.3    Bakke, S.4    Kotz, H.5    Thambi, P.6    Rutt, A.7    Balis, F.M.8    Bates, S.9    Fojo, T.10
  • 20
    • 34248183039 scopus 로고    scopus 로고
    • Ixabepilone given weekly in patients with advanced malignancies: Final efficacy and safety results of a phase i trial
    • abstract
    • Dickson N, Peck R, Wu C, Burris H. Ixabepilone given weekly in patients with advanced malignancies: final efficacy and safety results of a phase I trial. Proc Amer Soc Clin Oncol 2006;24:abstract 2040
    • (2006) Proc Amer Soc Clin Oncol , vol.24 , pp. 2040
    • Dickson, N.1    Peck, R.2    Wu, C.3    Burris, H.4
  • 22
    • 58149355287 scopus 로고    scopus 로고
    • A phase i and pharmacokinetic study of ixabepilone in combination with carboplatin in patients with advanced solid malignancies
    • Plummer R, Woll P, Fyfe D, et al. A phase I and pharmacokinetic study of ixabepilone in combination with carboplatin in patients with advanced solid malignancies. Clin Cancer Res 2008;14:8288-94
    • (2008) Clin Cancer Res , vol.14 , pp. 8288-8294
    • Plummer, R.1    Woll, P.2    Fyfe, D.3
  • 23
    • 84866155376 scopus 로고    scopus 로고
    • Phase II trial of ixabepilone and carboplatin with or without bevacizumab in patients with previously untreated advanced non-small-cell lung cancer
    • Spigel DR, Greco FA, Waterhouse DM, et al. Phase II trial of ixabepilone and carboplatin with or without bevacizumab in patients with previously untreated advanced non-small-cell lung cancer. Lung Cancer 2012;78:70-5
    • (2012) Lung Cancer , vol.78 , pp. 70-75
    • Spigel, D.R.1    Greco, F.A.2    Waterhouse, D.M.3
  • 24
    • 84874596625 scopus 로고    scopus 로고
    • Phase II trial of bevacizumab (B) and ixabepilone (Ix) for advanced non-squamous NSCLC progressive after first-line therapy
    • abstract e
    • Sanborn RE, Mack PC, Beckett L. Phase II trial of bevacizumab (B) and ixabepilone (Ix) for advanced non-squamous NSCLC progressive after first-line therapy. J Clin Oncol 2012;30(Suppl):abstract e 13550
    • (2012) J Clin Oncol , vol.30 , Issue.SUPPL. , pp. 13550
    • Sanborn, R.E.1    Mack, P.C.2    Beckett, L.3
  • 25
    • 33644831567 scopus 로고    scopus 로고
    • Phase i dose-finding study of weekly single-agent patupilone in patients with advanced solid tumors
    • Rubin E, Rothermel J, Tesfaye F, et al. Phase I dose-finding study of weekly single-agent patupilone in patients with advanced solid tumors. J Clin Oncol 2005;23:9120-9
    • (2005) J Clin Oncol , vol.23 , pp. 9120-9129
    • Rubin, E.1    Rothermel, J.2    Tesfaye, F.3
  • 26
    • 0000155381 scopus 로고    scopus 로고
    • A phase i clinical and pharmacokinetic study of EPO906 (Epothilone B), given every three weeks, in patients with advanced solid tumors
    • abstract
    • Calvert P, O'Neill V, Twelves C, et al. A phase I clinical and pharmacokinetic study of EPO906 (Epothilone B), given every three weeks, in patients with advanced solid tumors. Proc Am Soc Clin Oncol 2001;20:abstract 429
    • (2001) Proc Am Soc Clin Oncol , vol.20 , pp. 429
    • Calvert, P.1    O'Neill, V.2    Twelves, C.3
  • 27
    • 57049125514 scopus 로고    scopus 로고
    • Efficacy and safety of patupilone in non-small cell lung cancer (NSCLC): A phase I/II trial
    • abstract
    • Sanchez J, Mellemgaard A, Perry M, et al. Efficacy and safety of patupilone in non-small cell lung cancer (NSCLC): a phase I/II trial. Proc Amer Soc Clin Oncol 2006;24:abstract 7104
    • (2006) Proc Amer Soc Clin Oncol , vol.24 , pp. 7104
    • Sanchez, J.1    Mellemgaard, A.2    Perry, M.3
  • 28
    • 78751546627 scopus 로고    scopus 로고
    • Activity of patupilone in advanced or metastatic non-small cell lung cancer: A phase II study [abstract]
    • Zatloukal P, Mellemgaard A, Sanchez JM, et al. Activity of patupilone in advanced or metastatic non-small cell lung cancer: a phase II study [abstract]. Ann Oncol 2008;19(8S):296P
    • (2008) Ann Oncol , vol.19 , Issue.8 S
    • Zatloukal, P.1    Mellemgaard, A.2    Sanchez, J.M.3
  • 29
    • 58749099669 scopus 로고    scopus 로고
    • Patupilone for the treatment of recurrent/progressive brain metastases in patients (pts) with non-small cell lung cancer (NSCLC): An open-label, multicenter, phase II study
    • abstract
    • Abrey L, Wen P, Govindan R, et al. Patupilone for the treatment of recurrent/progressive brain metastases in patients (pts) with non-small cell lung cancer (NSCLC): an open-label, multicenter, phase II study. J Clin Oncol 2008;26(15S):abstract 2033
    • (2008) J Clin Oncol , vol.26 , Issue.15 S , pp. 2033
    • Abrey, L.1    Wen, P.2    Govindan, R.3
  • 30
    • 33646547391 scopus 로고    scopus 로고
    • A phase i study of the novel, third generation epothilone ZK-EPO in patients with advanced solid tumors
    • abstract
    • Schmid P, Kiewe P, Kuehnhardt D, et al. A phase I study of the novel, third generation epothilone ZK-EPO in patients with advanced solid tumors. J Clin Oncol 2005;23:abstract 2051
    • (2005) J Clin Oncol , vol.23 , pp. 2051
    • Schmid, P.1    Kiewe, P.2    Kuehnhardt, D.3
  • 31
    • 42549103468 scopus 로고    scopus 로고
    • Phase II trial of the novel epothilone ZK-EPO as second-line therapy in patients with stage IIIB or stage IV non-small-cell lung cancer
    • Gatzemeier U, von Pawel J, Eschbach C, et al. Phase II trial of the novel epothilone ZK-EPO as second-line therapy in patients with stage IIIB or stage IV non-small-cell lung cancer. EJC Suppl 2007;5(4):378
    • (2007) EJC Suppl , vol.5 , Issue.4 , pp. 378
    • Gatzemeier, U.1    Von Pawel, J.2    Eschbach, C.3
  • 33
    • 8344260820 scopus 로고    scopus 로고
    • Phase i study using continuous intravenous (CI) KOS-862 (Epothilone D) in patients with solid tumors
    • abstract
    • Holen K, Syed S, Hannah A, et al. Phase I study using continuous intravenous (CI) KOS-862 (Epothilone D) in patients with solid tumors. Proc Amer Soc Clin Oncol 2004;23:abstract 2024
    • (2004) Proc Amer Soc Clin Oncol , vol.23 , pp. 2024
    • Holen, K.1    Syed, S.2    Hannah, A.3
  • 34
    • 3142755834 scopus 로고    scopus 로고
    • KOS-862 (Epothilone D): Phase 1 dose escalating and pharmacokinetic (PK) study in patients with advanced malignancies
    • abstract
    • Spriggs D, Dupont J, Pezzulli A, et al. KOS-862 (Epothilone D): phase 1 dose escalating and pharmacokinetic (PK) study in patients with advanced malignancies. Proc Amer Soc Clin Oncol 2003;22:abstract 894
    • (2003) Proc Amer Soc Clin Oncol , vol.22 , pp. 894
    • Spriggs, D.1    Dupont, J.2    Pezzulli, A.3
  • 35
    • 2442505920 scopus 로고    scopus 로고
    • KOS-862 (epothilone D): A comparison of two schedules in patients with advanced malignancies
    • abstract
    • Piro L, Rosen L, Parson M, et al. KOS-862 (epothilone D): a comparison of two schedules in patients with advanced malignancies. Proc Amer Soc Clin Oncol 2003;22:abstract 539
    • (2003) Proc Amer Soc Clin Oncol , vol.22 , pp. 539
    • Piro, L.1    Rosen, L.2    Parson, M.3
  • 36
    • 31344455354 scopus 로고    scopus 로고
    • A phase II study of KOS-862 (Epothilone D) as second-line therapy in non-small cell lung cancer
    • abstract
    • Yee L, Lynch T, Villalona-Calero M, et al. A phase II study of KOS-862 (Epothilone D) as second-line therapy in non-small cell lung cancer. Proc Amer Soc Clin Oncol 2005;23:abstract 7127
    • (2005) Proc Amer Soc Clin Oncol , vol.23 , pp. 7127
    • Yee, L.1    Lynch, T.2    Villalona-Calero, M.3
  • 37
    • 84855686899 scopus 로고    scopus 로고
    • A phase II study of eribulin mesylate (E7389) in patients with advanced, previously treated non-small-cell lung cancer
    • Spira AI, Iannotti NO, Savin MA, et al. A phase II study of eribulin mesylate (E7389) in patients with advanced, previously treated non-small-cell lung cancer. Clin Lung Cancer 2012;13(1):31-8
    • (2012) Clin Lung Cancer , vol.13 , Issue.1 , pp. 31-38
    • Spira, A.I.1    Iannotti, N.O.2    Savin, M.A.3
  • 38
    • 84863831074 scopus 로고    scopus 로고
    • Eribulin mesylate (E7389) review of efficacy and tolerability in breast, pancreatic, head and neck, and non small cell lung cancer
    • Scarpace SL. Eribulin mesylate (E7389) review of efficacy and tolerability in breast, pancreatic, head and neck, and non small cell lung cancer. Clin Ther 2012;34(7):1467-73
    • (2012) Clin Ther , vol.34 , Issue.7 , pp. 1467-1473
    • Scarpace, S.L.1
  • 40
    • 76649120544 scopus 로고    scopus 로고
    • Aurora kinase inhibitors-Rising stars in cancer therapeutics?
    • Dar AA, Goff LW, Majid S, et al. Aurora kinase inhibitors-rising stars in cancer therapeutics? Mol Cancer Ther 2010;9:268-78
    • (2010) Mol Cancer Ther , vol.9 , pp. 268-278
    • Dar, A.A.1    Goff, L.W.2    Majid, S.3
  • 41
    • 0037084163 scopus 로고    scopus 로고
    • -/- cells
    • DOI 10.1093/emboj/21.4.483
    • Meraldi P, Honda R, Nigg EA. Aurora-A overexpression reveals tetraploidization as a major route to centrosome amplification in p53-/-cells. EMBO J 2002;21:483-92 (Pubitemid 34174030)
    • (2002) EMBO Journal , vol.21 , Issue.4 , pp. 483-492
    • Meraldi, P.1    Honda, R.2    Nigg, E.A.3
  • 42
    • 33750374052 scopus 로고    scopus 로고
    • A phase i clinical and pharmacokinetic (pk) trial of the aurora kinase (ak) inhibitor mk-0457 in cancer patients
    • abstract
    • Rubin E, Shapiro G, Stein M, et al. A phase I clinical and pharmacokinetic (PK) trial of the aurora kinase (AK) inhibitor MK-0457 in cancer patients. Proc Amer Soc Clin Oncol 2006;24:abstract 3009
    • (2006) Proc Amer Soc Clin Oncol , vol.24 , pp. 3009
    • Rubin, E.1    Shapiro, G.2    Stein, M.3
  • 43
    • 70349156095 scopus 로고    scopus 로고
    • Phase i pharmacokinetic (pk) and pharmacodynamic (pd) study of the selective aurora a kinase (aak) inhibitor mln8054 in patients (pts) with advanced solid tumors
    • abstract
    • Macarulla T, Rodr?guez-Braun E, Tabernero J, et al. Phase I pharmacokinetic (PK) and pharmacodynamic (PD) study of the selective aurora A kinase (AAK) inhibitor MLN8054 in patients (pts) with advanced solid tumors. J Clin Oncol 2009;27(15s Suppl):abstract 2578
    • (2009) J Clin Oncol , vol.27 , Issue.15 SUPPL. , pp. 2578
    • Macarulla, T.1    Rodrguez-Braun, E.2    Tabernero, J.3
  • 44
    • 70349156095 scopus 로고    scopus 로고
    • Phase i pharmacokinetic (PK) and pharmacodynamic (PD) study of MLN8237, a novel selective aurora A kinase (AAK) inhibitor, in patients (pts) with advanced solid tumors
    • abstract
    • Cervantes-Ruiperez A, Elez ME, Rosello S, et al. Phase I pharmacokinetic (PK) and pharmacodynamic (PD) study of MLN8237, a novel selective aurora A kinase (AAK) inhibitor, in patients (pts) with advanced solid tumors. J Clin Oncol 2009;15s Suppl):abstract 2565
    • (2009) J Clin Oncol , Issue.15 SUPPL. , pp. 2565
    • Cervantes-Ruiperez, A.1    Elez, M.E.2    Rosello, S.3
  • 45
    • 84874626828 scopus 로고    scopus 로고
    • Phase i/ii study of the investigational aurora a kinase (aak) inhibitor mln8237 (alisertib) in patients (pts) with non-small cell lung cancer (nsclc), small cell lung cancer (sclc), breast cancer (brc), head/neck cancer (h&n), and gastroesophageal (ge) adenocarcinoma: Preliminary phase ii results
    • SMay 20
    • Lee P, Alvarez RH, Melichar B, et al. Phase I/II study of the investigational aurora A kinase (AAK) inhibitor MLN8237 (alisertib) in patients (pts) with non-small cell lung cancer (NSCLC), small cell lung cancer (SCLC), breast cancer (BrC), head/neck cancer (H&N), and gastroesophageal (GE) adenocarcinoma: preliminary phase II results. 2012 ASCO Annual Meeting Proceedings (Post-Meeting Edition). J Clin Oncol 2012;30(15S May 20 Suppl):3010
    • (2012) 2012 ASCO Annual Meeting Proceedings (Post-Meeting Edition). J Clin Oncol , vol.30 , Issue.15 SUPPL. , pp. 3010
    • Lee, P.1    Alvarez, R.H.2    Melichar, B.3
  • 46
    • 84874620450 scopus 로고    scopus 로고
    • Relationship of Aurora-A kinase and EGFR inhibition in non-small cell lung cancer (NSCLC) cell lines
    • abstract
    • Zhang J, Pan X, Astsaturov IA, et al. Relationship of Aurora-A kinase and EGFR inhibition in non-small cell lung cancer (NSCLC) cell lines. J Clin Oncol 2011;29(Suppl):abstract e13038
    • (2011) J Clin Oncol , vol.29 , Issue.SUPPL.
    • Zhang, J.1    Pan, X.2    Astsaturov, I.A.3
  • 47
    • 70249137888 scopus 로고    scopus 로고
    • A phase i study of AT9283, an aurora kinase inhibitor, in patients with refractory solid tumors
    • abstract
    • Kristeleit R, Calvert H, Arkenau H, et al. A phase I study of AT9283, an aurora kinase inhibitor, in patients with refractory solid tumors. J Clin Oncol 2009;27(15s Suppl):abstract 2566
    • (2009) J Clin Oncol , vol.27 , Issue.15 SUPPL. , pp. 2566
    • Kristeleit, R.1    Calvert, H.2    Arkenau, H.3
  • 48
    • 80054109912 scopus 로고    scopus 로고
    • Polo-like kinase 1 inhibitors and their potential role in anticancer therapy, with a focus on NSCLC
    • Medema RH, Lin CC, Yang JC. Polo-like kinase 1 inhibitors and their potential role in anticancer therapy, with a focus on NSCLC. Clin Cancer Res 2011;17:6459-66
    • (2011) Clin Cancer Res , vol.17 , pp. 6459-6466
    • Medema, R.H.1    Lin, C.C.2    Yang, J.C.3
  • 51
    • 0035990398 scopus 로고    scopus 로고
    • Expression of polo-like kinase (PLK1) in thin melanomas: A novel marker of metastatic disease
    • Kneisel L, Strebhardt K, Bernd A, et al. Expression of polo-like kinase (PLK1) in thin melanomas: a novel marker of metastatic disease. J Cutan Pathol 2002;29:354-8
    • (2002) J Cutan Pathol , vol.29 , pp. 354-358
    • Kneisel, L.1    Strebhardt, K.2    Bernd, A.3
  • 52
    • 16844369144 scopus 로고    scopus 로고
    • Small interfering RNA-mediated polo-like kinase 1 depletion preferentially reduces the survival of p53-defective, oncogenic transformed cells and inhibits tumor growth in animals
    • DOI 10.1158/0008-5472.CAN-04-2131
    • Guan R, Tapang P, Leverson JD, et al. Small interfering RNA-mediated pololike kinase 1 depletion preferentially reduces the survival of p53-defective, oncogenic transformed cells and inhibits tumor growth in animals. Cancer Res 2005;65:2698-704 (Pubitemid 40490070)
    • (2005) Cancer Research , vol.65 , Issue.7 , pp. 2698-2704
    • Guan, R.1    Tapang, P.2    Leverson, J.D.3    Albert, D.4    Giranda, V.L.5    Luo, Y.6
  • 53
    • 68049095649 scopus 로고    scopus 로고
    • A phase i dose escalation trial of BI 2536, a novel Plk1 inhibitor, with standard dose pemetrexed in previously treated advanced or metastatic non-small cell lung cancer (NSCLC)
    • abstract
    • Ellis PM, Chu QS, Leighl NB, et al. A phase I dose escalation trial of BI 2536, a novel Plk1 inhibitor, with standard dose pemetrexed in previously treated advanced or metastatic non-small cell lung cancer (NSCLC). J Clin Oncol 2008;26(Suppl):abstract 8115
    • (2008) J Clin Oncol , vol.26 , Issue.SUPPL. , pp. 8115
    • Ellis, P.M.1    Chu, Q.S.2    Leighl, N.B.3
  • 54
    • 77954423900 scopus 로고    scopus 로고
    • The efficacy and safety of BI 2536, a novel Plk-1 inhibitor, in patients with stage IIIB/IV non-small cell lung cancer who had relapsed after, or failed, chemotherapy: Results from an open-label, randomized phase II clinical trial
    • Sebastian M, Reck M, Waller CF, et al. The efficacy and safety of BI 2536, a novel Plk-1 inhibitor, in patients with stage IIIB/IV non-small cell lung cancer who had relapsed after, or failed, chemotherapy: results from an open-label, randomized phase II clinical trial. J Thorac Oncol 2010;5:1060-7
    • (2010) J Thorac Oncol , vol.5 , pp. 1060-1067
    • Sebastian, M.1    Reck, M.2    Waller, C.F.3
  • 55
    • 84857120350 scopus 로고    scopus 로고
    • Final analysis of a phase i single dose-escalation study of the novel polo-like kinase 1 inhibitor BI 6727 in patients with advanced solid tumors
    • abstract
    • Gil T, Schoffski P, Awada A, et al. Final analysis of a phase I single dose-escalation study of the novel polo-like kinase 1 inhibitor BI 6727 in patients with advanced solid tumors. J Clin Oncol 2010;28(Suppl 15):abstract 3061
    • (2010) J Clin Oncol , vol.28 , Issue.SUPPL. 15 , pp. 3061
    • Gil, T.1    Schoffski, P.2    Awada, A.3
  • 56
    • 84874606380 scopus 로고    scopus 로고
    • Phase i trial of the polo-like kinase (Plk) inhibitor volasertib (BI 6727) combined with cisplatin or carboplatin in patients with advanced solid tumors
    • abstract
    • Dumez H, Gombos A, Schoffski P, et al. Phase I trial of the polo-like kinase (Plk) inhibitor volasertib (BI 6727) combined with cisplatin or carboplatin in patients with advanced solid tumors. J Clin Oncol 2012;30(Suppl): abstract 3018
    • (2012) J Clin Oncol , vol.30 , Issue.SUPPL.
    • Dumez, H.1    Gombos, A.2    Schoffski, P.3
  • 58
    • 33846558079 scopus 로고    scopus 로고
    • Differential gene expression analysis of kinesin spindle protein in human solid tumors
    • abstract
    • Hegde P, Cogswell J, Carrick K, et al. Differential gene expression analysis of kinesin spindle protein in human solid tumors. Proc Amer Soc Clin Oncol 2003;22:abstract 535
    • (2003) Proc Amer Soc Clin Oncol , vol.22 , pp. 535
    • Hegde, P.1    Cogswell, J.2    Carrick, K.3
  • 59
    • 84866674984 scopus 로고    scopus 로고
    • The structure of the ternary Eg5-ADP-ispinesib complex
    • Talapatra SK, Schuttelkopf AW, Kozielski F. The structure of the ternary Eg5-ADP-ispinesib complex. Acta Cryst 2012;68:1311-19
    • (2012) Acta Cryst , vol.68 , pp. 1311-1319
    • Talapatra, S.K.1    Schuttelkopf, A.W.2    Kozielski, F.3
  • 60
    • 20344406651 scopus 로고    scopus 로고
    • Phase i trial of novel kinesin spindle protein (ksp) inhibitor sb-715992 iv q 21 days
    • abstract
    • Chu Q, Holen K, Rowinsky E, et al. Phase I trial of novel kinesin spindle protein (KSP) inhibitor SB-715992 IV Q 21 days. Proc Amer Soc Clin Oncol 2004;22:abstract 2078
    • (2004) Proc Amer Soc Clin Oncol , vol.22 , pp. 2078
    • Chu, Q.1    Holen, K.2    Rowinsky, E.3
  • 61
    • 33845318699 scopus 로고    scopus 로고
    • Phase i study of ispinesib in combination with carboplatin in patients with advanced solid tumors
    • S June 20
    • Jones SF, Plummer ER, Burris HA, et al. Phase I study of ispinesib in combination with carboplatin in patients with advanced solid tumors. 2006 ASCO Annual Meeting Proceedings Part I. J Clin Oncol 2006;24(18S June 20 Suppl):2027
    • (2006) 2006 ASCO Annual Meeting Proceedings Part I. J Clin Oncol , vol.24 , Issue.18 SUPPL. , pp. 2027
    • Jones, S.F.1    Plummer, E.R.2    Burris, H.A.3
  • 62
    • 84874625448 scopus 로고    scopus 로고
    • Cytokinetics Reports Data for Ispinesib (SB-715992) in Platinum-Sensitive Non- Small Cell Lung Cancer
    • Cytokinetics Reports Data for Ispinesib (SB-715992) in Platinum-Sensitive Non- Small Cell Lung Cancer. Available from: http://www.prnewswire.com/ newsreleases/cytokinetics-reports-data-forispinesib- sb-715992-in- platinumsensitive- non-small-cell-lung-cancer- 70742202.html


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.